The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
N | Nervous system | |
2
|
N06 | Psychoanaleptics | |
3
|
N06D | Anti-dementia drugs | |
4
|
N06DX | Other anti-dementia drugs | |
5
|
N06DX04 |
| Active Ingredient |
|---|
|
Lecanemab is an IgG1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta and reduces amyloid beta plaques. |
| Document | Type | Information Source | |
|---|---|---|---|
| LEQEMBI Concentrate for solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) | |
| LEQEMBI Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.